Table 2.
Demographics, cognitive scores, APOE genotype, self-reported comorbidities, medication use and availability of eye imaging factors for UK Biobank participants attending the baseline imaging assessment to date (N=48 998)
| Characteristics | n (%) or mean (SD) |
| Age (years) | 55.2 (7.6) |
| Sex | |
| Female | 25 290 (52%) |
| Male | 23 708 (48%) |
| Cognitive scores at baseline assessment | |
| Numeric memory: maximum digits remembered correctly (n=4911) | 6.97 (1.25) |
| Fluid intelligence score (n=16 427) | 6.68 (2.04) |
| Prospective memory test (n=16 544) | 1.10 (0.36) |
| Snap game: mean time to correctly identify matches (ms) (n=48 858) | 539.2 (101.3) |
| Pairs matching: number of incorrect matches in round (n=24 988) | 0.66 (1.24) |
| APOE genotype | |
| ε3ε3 | 28 297 (59%) |
| ε3ε4 | 11 063 (23%) |
| ε2ε3 | 5892 (12%) |
| ε2ε4 | 1128 (2%) |
| ε4ε4 | 1065 (2%) |
| ε2ε2 | 277 (1%) |
| Comorbidities | |
| Hypertension | 13 666 (28%) |
| Diabetes | 2008 (4%) |
| Ischaemic heart disease | 2649 (5%) |
| Stroke | 719 (1%) |
| Chronic obstructive pulmonary disease | 1016 (2%) |
| Asthma | 6689 (14%) |
| Obesity (BMI>30 kg/m2) | 8918 (18%) |
| Parkinson’s disease | 136 (<1%) |
| Alzheimer’s disease | 34 (<1%) |
| Multiple sclerosis | 202 (<1%) |
| Medication use | |
| Anti-hypertensive | 9769 (20%) |
| Statin | 8750 (18%) |
| Eye imaging available | 13 732 (28%) |
Mean (SD) is presented for continuous variables and count (%) for categorical variables. All variables are presented for the full sample except for APOE genotype (1276 missing) and for cognitive scores (numbers of participants for each test at any phase of UK Biobank examinations are presented in the table).
APOE, apolipoprotein E; BMI, body mass index.